Caladrius Biosciences (CLBS) Reports Q3 Loss Per Share of $1.33

August 9, 2016 5:33 PM EDT
Get Alerts CLBS Hot Sheet
Price: $3.66 --0%

Today's EPS Names:
Trade CLBS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Caladrius Biosciences (NASDAQ: CLBS) reported Q2 EPS of ($1.33), may not compare to the analyst estimate of ($1.75). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.53 million.

2016 Financial Guidance

The Company reaffirms its previous guidance as follows:

  • Consolidated Revenues: to exceed $30 million or a greater than 30% increase compared with 2015
  • Capital Improvements at PCT’s Allendale, NJ facility: ~$6 million, to be completed by end of first half of 2017
  • CLBS03 Phase 2 Study Costs in 2016: $6 million to $7 million
  • Consolidated Annual Operating Cash Burn: $25 million to $28 million in 2016, with lower operating cash burn in the second half of 2016 than in the first half of the year

For earnings history and earnings-related data on Caladrius Biosciences (CLBS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment